Moderna (MRNA) Receives U.S. FDA Approval for RSV Vaccine mRESVIA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Moderna (MRNA) PT Raised to $160 at RBC Capital
June 3, 2024 6:40 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $160.00 (from $135.00) while maintaining a Outperform rating.
The analyst comments "Despite PDUFA date pushed out by a few weeks, MRNA gets approved for RSV. Vaccine efficacy reported on the label (79%)... More
